Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

David M. Hyams; Avital Bareket-Samish; Juan Enrique Bargallo Rocha; Sebastian Diaz-Botero; Sandra Franco; Debora Gagliato; Henry L. Gomez; Ernesto Korbenfeld; Gabriel Krygier; Andre Mattar; Aníbal Nuñez De Pierro; Manuel Ruiz Borrego; Cynthia Villarreal

doi:10.1002/jso.27692

Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

David M. Hyams
, Avital Bareket-Samish
, Juan Enrique Bargallo Rocha
, Sebastian Diaz-Botero
, Sandra Franco
, Debora Gagliato
, Henry L. Gomez
, Ernesto Korbenfeld
, Gabriel Krygier
, Andre Mattar
, Aníbal Nuñez De Pierro
, Manuel Ruiz Borrego
, Cynthia Villarreal

Eisenhower Medical Center
BioInsight Ltd.
ABC Medical Center
Clinica Universidad De Navarra
CTIC
Beneficencia Portuguesa de Sao Paulo
Universidad Ricardo Palma
Hospital Británico
Hospital de Clinicas Dr. Manuel Quintela
Hospital da Mulher
Hospital General de Agudos Juan A Fernández
Hospital Universitario Virgen del Rocío
Hospital Zambrano Hellion TecSalud

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Gene expression assays (GEAs) can guide treatment for early-stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index®, EndoPredict®, MammaPrint®, Oncotype DX®, and Prosigna®). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.

Original language	English
Pages (from-to)	166-187
Number of pages	22
Journal	Journal of Surgical Oncology
Volume	130
Issue number	2
DOIs	https://doi.org/10.1002/jso.27692
State	Published - Aug 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

adjuvant chemotherapy
adjuvant drug therapy
biomarkers
breast neoplasms
clinical decision support systems
gene expression
prognosis

Access to Document

10.1002/jso.27692

Cite this

Hyams, D. M., Bareket-Samish, A., Rocha, J. E. B., Diaz-Botero, S., Franco, S., Gagliato, D., Gomez, H. L., Korbenfeld, E., Krygier, G., Mattar, A., De Pierro, A. N., Borrego, M. R., & Villarreal, C. (2024). Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays. Journal of Surgical Oncology, 130(2), 166-187. https://doi.org/10.1002/jso.27692

@article{0656bbe411314a55a5fee4e0bd88ef78,

title = "Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays",

abstract = "Gene expression assays (GEAs) can guide treatment for early-stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index{\textregistered}, EndoPredict{\textregistered}, MammaPrint{\textregistered}, Oncotype DX{\textregistered}, and Prosigna{\textregistered}). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.",

keywords = "adjuvant chemotherapy, adjuvant drug therapy, biomarkers, breast neoplasms, clinical decision support systems, gene expression, prognosis",

author = "Hyams, \{David M.\} and Avital Bareket-Samish and Rocha, \{Juan Enrique Bargallo\} and Sebastian Diaz-Botero and Sandra Franco and Debora Gagliato and Gomez, \{Henry L.\} and Ernesto Korbenfeld and Gabriel Krygier and Andre Mattar and \{De Pierro\}, \{An{\'i}bal Nu{\~n}ez\} and Borrego, \{Manuel Ruiz\} and Cynthia Villarreal",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Journal of Surgical Oncology published by Wiley Periodicals LLC.",

year = "2024",

month = aug,

doi = "10.1002/jso.27692",

language = "Ingl{\'e}s",

volume = "130",

pages = "166--187",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

number = "2",

}

Hyams, DM, Bareket-Samish, A, Rocha, JEB, Diaz-Botero, S, Franco, S, Gagliato, D, Gomez, HL, Korbenfeld, E, Krygier, G, Mattar, A, De Pierro, AN, Borrego, MR & Villarreal, C 2024, 'Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays', Journal of Surgical Oncology, vol. 130, no. 2, pp. 166-187. https://doi.org/10.1002/jso.27692

Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays. / Hyams, David M.; Bareket-Samish, Avital; Rocha, Juan Enrique Bargallo et al.
In: Journal of Surgical Oncology, Vol. 130, No. 2, 08.2024, p. 166-187.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Selecting postoperative adjuvant systemic therapy for early-stage breast cancer

T2 - An updated assessment and systematic review of leading commercially available gene expression assays

AU - Hyams, David M.

AU - Bareket-Samish, Avital

AU - Rocha, Juan Enrique Bargallo

AU - Diaz-Botero, Sebastian

AU - Franco, Sandra

AU - Gagliato, Debora

AU - Gomez, Henry L.

AU - Korbenfeld, Ernesto

AU - Krygier, Gabriel

AU - Mattar, Andre

AU - De Pierro, Aníbal Nuñez

AU - Borrego, Manuel Ruiz

AU - Villarreal, Cynthia

PY - 2024/8

Y1 - 2024/8

N2 - Gene expression assays (GEAs) can guide treatment for early-stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index®, EndoPredict®, MammaPrint®, Oncotype DX®, and Prosigna®). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.

AB - Gene expression assays (GEAs) can guide treatment for early-stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index®, EndoPredict®, MammaPrint®, Oncotype DX®, and Prosigna®). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.

KW - adjuvant chemotherapy

KW - adjuvant drug therapy

KW - biomarkers

KW - breast neoplasms

KW - clinical decision support systems

KW - gene expression

KW - prognosis

UR - https://www.scopus.com/pages/publications/85196753524

U2 - 10.1002/jso.27692

DO - 10.1002/jso.27692

M3 - Artículo de revisión

C2 - 38932668

AN - SCOPUS:85196753524

SN - 0022-4790

VL - 130

SP - 166

EP - 187

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 2

ER -

Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this